Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pediatric Patients with CD & Development of Strictures

Clin Gastroenterol Hepatol; ePub 2018 Sep 10; Ballengee, et al

Median plasma concentrations of collagen type III alpha chain (COL3A1) was significantly higher in patients with Crohn’s disease (CD) who later developed strictures than in patients without strictures, a new study found. Researchers selected 161 individuals (mean age 12.2 years, 62% male) from the Risk Stratification and Identification of Immunogenic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s cohort, which was completed at 28 sites in the US and Canada from 2008 through 2012. The children underwent colonoscopy and upper endoscopy at diagnosis and were followed every 6 months for 36 months. Based on CD phenotype, children were separated to group 1 (B1 phenotype at diagnosis and follow up), group 2 (B2 phenotype at diagnosis), or group 3 (B1 phenotype at diagnosis who developed strictures during follow up). Plasma samples were collected from patients and 40 children without inflammatory bowel disease (controls) at baseline and analyzed by ELISA to measure COL3A1 and cartilage oligomeric matrix protein (COMP). Researchers found:

  • The median baseline concentration of COL3A1 was significantly higher in plasma from group 3 vs group 1 and controls.
  • Median baseline plasma concentrations of COMP did not differ significantly among groups.
  • The combination of concentrations of COL3A1 and anti-CSF2 may be used to identify pediatric patients at CD diagnosis who are at risk for future strictures.


Ballengee CR, Stidham RW, Liu C, et al. Association between plasma level of collagen type III alpha 1 chain and development of strictures in pediatric patients with Crohn’s disease. [Published online ahead of print September 10, 2018]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.09.008.